According to the American Heart Association, although overall cardiovascular death rates have declined since 2001, one in three women still suffers from some form of cardiovascular disease. Despite stunning improvements in women’s cardiovascular cardiovascular mortality in the past two decades, heart disease remains understudied, under diagnosed and undertreated in women.
In half of all heart attacks among women, typical male symptoms are not present. Without acknowledging and differentiating treatments between men and women, heart disease will continue to pose a major threat.
Cardiac programs across the country must be prepared to handle the unique needs of the female cardiac patient. The prevalence of cardiovascular complications in women means that designing and managing an efficient Women’s Cardiac Department is more crucial than ever.
With women being the key healthcare decision makers, its business significance makes it a vital area of focus. ACI’s Women’s Cardiovascular Programs & Services will provide participants with the expert knowledge and tools to reduce costs, enhance revenue, and increase the overall market share of their Women’s Cardiac Departments.
Join us February 2-3, 2017 for a gathering of administrative and medical leaders. This three-day strategic business conference will focus on how hospitals and health systems can profitably expand their Women’s Cardiac facilities to meet the increased demand for gender-specialized services. Learn how to build a comprehensive, multi-disciplinary Women’s Cardiac organization to bring the most progressive care to each patient. With the level of severity that Cardiac disease poses to our population, this is a conference that you cannot afford to miss.
Florida Hospital Pepin Heart Institute, located at Florida Hospital Tampa, is a free-standing cardiovascular institute providing comprehensive cardiovascular care. Leading the way with the first accredited chest pain emergency room in Tampa Bay, the institute was among an elite few in the state of Florida chosen to first perform the ground breaking Transcatheter Aortic Valve Replacement (TAVR) procedure and was the first hospital in Tampa to offer the Watchman procedure to patients with atrial fibrillation. Florida Hospital Pepin Heart Institute and the Dr. Kiran C. Patel Research Institute, affiliated with the University of South Florida (USF), are exploring and conducting leading-edge research to develop break-through treatments long before they are available in most other hospitals.
The conference is ideally suited for administrators and senior level health professionals involved in the care of Female Cardiac Patients—Representing the Women’s Cardiac Departments of Community Hospitals, Health Systems, Academic Medical Centers, and Hospital Networks.
Key titles include:
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human biologic and small molecule medicines and vaccines, as well as many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases. Around the world, our medicines help millions of people in their fight against such diseases as cancer, cardiovascular disease, hepatitis B and hepatitis C, HIV/AIDS and, rheumatoid arthritis.
Cardiovascular executives and physicians have been in the forefront of innovation in healthcare, from setting standards for quality metrics and appropriate use to being at the vanguard in new reimbursement and employment models. Since 2007, Cardiovascular Business has provided critical information to help clinical and administrative decision makers navigate changes in healthcare.
Gender and the Genome, a new peer-reviewed journal, will explore how the new science of the 21st century is profoundly influenced by biological sex. Through evidence-based original research, reviews, perspectives, and commentaries, the Journal will illuminate the impact of biological sex on technology and its effects on human life
Journal of Women’s Health is the primary source of information for meeting the challenges of providing optimal health care for women throughout their lifespan. The Journal delivers cutting-edge advancements in diagnostic procedures, therapeutic protocols for the management of diseases, and innovative research in gender-based biology that impacts patient care and treatment.
The Society for Women’s Health Research (SWHR®), is a national non-profit based in Washington D.C. that is widely recognized as the thought-leader in promoting research on biological differences in disease and is dedicated to transforming women’s health through science, advocacy, and education. Founded in 1990 by a group of physicians, medical researchers and health advocates, SWHR aims to bring attention to the variety of diseases and conditions that disproportionately or predominantly affect women.